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Abstract
Neuroendocrine tumors (NETs) are an uncommon diagnosis which often present asymptomatically or with vague symp-
toms. They can originate from many different organs such as the GI tract, lungs, pancreas and others. 68Gallium DOTATATE
positron emission topography/computed topography has been shown to be an effective imaging modality for diagnosing
NET and evaluating management options for patients. Here, we present two cases of positive findings in the distal pancreas
on the DOTATATE PET/CT scans without any morphological lesion found to be NET in a healthy 48-year-old male and
68-year-old male.
INTRODUCTION
Neuroendocrine tumors (NETs) originate from neuroendocrine
cells and are predominantly found in the respiratory or gastro-
intestinal tract. The incidence has increased over the past dec-
ades [1]. Due to their heterogeneity, nonspecific presentation
symptoms, and indolent behavior, patients with NETs may
undergo significant delay in diagnosis [1].
It was discovered that well differentiated NETs express high
levels of somatostatin receptors [6] and thus somatostatin receptor
imaging was born. 111Indium-DTPA-penteoctreotide (Octreoscan)
was one of the first functional imaging modalities to diagnose
NET, yet, it suffered from limited imaging quality and spatial reso-
lution as well as prolonged imaging protocols [2]. Recently,
68Gallium-DOTA-D-Phe1-Tyr3-Thr8-octreotide positron emission
topography/computed topography (DOTATATE PET/CT) imaging
has shown to be superior to Octreoscan [3]. This has led to a
uniquely quick adoption of this imaging modality for the detection
of NETs.
Endoscopic ultrasound (EUS) has been shown to accurately
localize pancreatic NET (PNET) with a high sensitivity and speci-
ficity [4]; detection can be limited by chronic pancreatitis, distal
pancreatic tail lesions and other factors [5]. Here, the following
case reports describe detecting PNET in two patients utilizing
68Gallium DOTATATE PET/CT imaging without preoperative tis-
sue diagnosis.
CASE PRESENTATION #1
A 48-year-old Caucasian male with a medical history significant
for hypertension was referred to the general surgery clinic for
chronic abdominal pain for the past 6 months. The patient was
suffering from nausea, postprandial facial flushing and crampy/
colicky epigastric pain radiating to the RLQ. Initial laboratory work
up including complete blood count, complete metabolic panel, ser-
um CA-19-9, serum CEA, urinary 5-HIAA, serum chromogranin A
and serum neuron specific enolase were all unremarkable.
Additionally, right upper quadrant ultrasound and CT abdomen/
pelvis were unremarkable. However, the patient symptoms per-
sisted, and therefore a 68Ga DOTATATE PET/CT scan was ordered.
Imaging revealed increased DOTATATE activity (SUV 9.7) in the
distal pancreatic tail without an underling mass on CT (Fig. 1A).
EUS fine needle aspiration was unremarkable. Additional labora-
tory analysis revealed elevated C-peptide (4.9 ng/ml) and
Received: July 16, 2018. Accepted: August 20, 2018
Published by Oxford University Press and JSCR Publishing Ltd. All rights reserved. © The Author(s) 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
1
proinsulin levels (76 pmol/l), concerning for an insulinoma. In add-
ition, a HIDA scan showed a gallbladder ejection fraction of 34%,
consistent with chronic cholecystitis.
Although there was no tissue diagnosis for the suspected insu-
linoma on the distal pancreas, a laparoscopic distal pancreatec-
tomy, splenectomy and cholecystectomy was recommended. Of
note, the intraoperative ultrasound of the pancreas was unremark-
able. The distal pancreas was removed and frozen section con-
firmed no insulinoma at the margins. Pathological examination
revealed microscopic (0.5 cm) well differentiated (KI 67 < 1%) NET
(Fig. 2). Six benign regional lymph nodes were also removed. In
addition, there was evidence of focal chronic pancreatitis. Patient
did well postoperatively.
Patient was compliant with his follow-up appointment at 1,
6 and 12 months. His preoperative symptoms have resolved.
His postoperative laboratory workup and imaging has been
negative for recurrence.
CASE PRESENTATION #2
A 68-year-old male with a medical history for hypertension and
type 2 diabetes mellitus, was referred to the general surgery
clinic with three bouts of acute pancreatitis of unclear etiology
from February 2017 to March 2018. He had intermittent severe
postprandial epigastric pain and nausea. Patient denied other
symptoms. Initial laboratory work up was unremarkable except
for an elevated chromogranin A (393ng/ml). CT abdomen and
pelvis as well as magnetic resonance cholangiopancreatogra-
phy were unable to identify any lesion. Therefore, the patient
underwent a 68Ga DOTATATE PET/CT scan which revealed
increased uptake in the distal pancreas (SUVmax 7.6) without
any underling lesion (Fig. 1B). EUS fine needle aspiration
showed no abnormalities. Given the multiple bouts of acute
pancreatitis, he was recommended to have a laparoscopic dis-
tal pancreatectomy and splenectomy. Intraoperative ultrasound
demonstrated a normal pancreas. Pathology revealed a NET
(10mm in size) and margins were negatives. Eleven benign
lymph nodes were resected. His 2-week postoperative follow
up in late April 2018 was unremarkable. He denied new symp-
toms and previous symptoms have resolved. No imaging or
laboratory work up was done at this time.
DISCUSSION
NETs are considered rare tumors. However, the incidence has
been increasing in the USA over the past decades [1]. They arise
from multiple different organs not limited to but include the GI
tract, pancreas, ovaries and pituitary gland [1]. These tumors
are indolent, slow growing and therefore, patients present
asymptomatically [6]. Some patients present with carcinoid
syndrome, a constellation of symptoms including mainly facial
flushing and diarrhea [1]. Pathologic values of urinary 5-HIAA
and chromogranin A levels are a common finding.
68Ga DOTATATE PET/CT scans are being utilized for the
diagnosis of NET. It has been shown previously to be superior
to its predecessor, Octreoscan [3]. Furthermore, this modality
has a sensitivity, specificity, and positive predictive value of 81,
90 and 81%, respectively, in patients with suspected NET [7]. In
addition, it is used in evaluating the treatment options, detect-
ing metastatic disease, and presence of recurrent disease [8].
Therefore, it is crucial for the management of NETs.
Figure 1: (A) 68Ga PET/CT DOTATATE demonstrating increased DOTATATE uptake (SUVmax 9.7) in the distal pancreas without underlying pancreatic mass in the first
case study. (B) In the second case study, 68Ga PET/CT DOTATATE revealed increased DOTATATE uptake (SUVmax 7.6) in the pancreatic tail without any CT
abnormality.
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Both cases exemplify the difficulty of establishing a preopera-
tive diagnosis of NET. The patients had laboratory evidence of an
NET, given the elevated C peptide and proinsulin in the first
patient and elevated chromogranin A in the second patient.
Although these markers are highly sensitive and specific for
NETs [9], there was no morphological evidence of any lesion.
However, both did have functional evidence of NET on the dis-
tal pancreas (Fig. 1). EUS studies were unremarkable and unable
to give a tissue diagnosis, which may have been secondary to
the presence of pancreatitis or the location of the lesions in the
distal pancreas. The patients underwent laparoscopic distal
pancreatectomy and splenectomy and there was microscopic
evidence for NET in the pathologic specimens.
In summary, these cases highlight the important of obtain-
ing a 68Ga DOTATATE PET/CT scan for patients for suspected
NET by history or biochemical evaluation with a paucity of
other cross-sectional imaging findings. Additionally, patients
can be considered for surgical resections of lesions that demon-
strate increased DOTATATE uptake without preoperative tissue
diagnosis as there is a high likelihood they are NETs.
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Figure 2: Pathology from the first operation on the first case study patient. (A) H&E stain at low magnification (×40) shows a well-defined border between the tumor
and normal pancreatic tissue (right lower). (B) High magnification (×200) shows the tumor cells forming anastomosing cords, with ‘salt-and-pepper’ chromatin and
eosinophilic, granular cytoplasm.
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